Frances F Canet, MD
Cardiovascular Disease (Cardiology) · Auburn
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 11
- Since medical school
- 19 years
- Graduated 2007
Offices
11 locations · Sutter Valley Medical Foundation · 2,473 clinicians in this group
Hospitals listed: Sutter Auburn Faith Hospital · Sutter Medical Center, Sacramento · Sutter Roseville Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Canet’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A127503 · Current
Licensed to practise in California · since 2013 · expires 2027-02-28 · Virginia Commonwealth University, Medical College of Virginia.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Cardiovascular Disease
- American Board of Internal Medicine - Internal Medicine
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sutter Auburn Faith HospitalAuburn, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Sutter Medical Center, SacramentoSacramento, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 13.9 (12 to 15.9) · 992 cases, Jan 2024 – Dec 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.066, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.335, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.215, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.46, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.253, Oct 2024 – Sep 2025
- Sutter Roseville Medical CenterRoseville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.08 (0 to 0.56) · 12,400 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.069, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.262, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.128, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.357, Oct 2024 – Sep 2025
See every measure and the patient survey for Sutter Auburn Faith Hospital
Behind the star rating — Deaths: 0 better, 6 the same, 0 worse of 6 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2.01) · 312 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.62 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 160.66 (100.73 to 220.58) · 26 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.5 · 63 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.7 · 160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16 · 241 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,272 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,484 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.08 to 0.5) · 2,442 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.11 (1.72 to 6.49) · 442 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.12 (0.47 to 3.78) · 417 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.72 (0.67 to 18.77) · 133 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.26 (4.11 to 12.4) · 113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.18) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.3) · 1,845 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 34 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.9 · 178 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -30.1 · 250 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.1 · 300 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.5) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8 to 16.4) · 58 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 95 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.7 (9 to 15.2) · 1,787 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 473 cases | No different | Jan 2024 – Dec 2024 |
What patients said (563 patients answered, 27% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 91% |
| Doctors "always" explained things so they could understand | 81% |
| Doctors "always" listened carefully | 82% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 51% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 53% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Medical Center, Sacramento
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.9 (12 to 15.9) · 992 cases | Worse | Jan 2024 – Dec 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.066 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.335 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.215 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.46 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.253 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.12 (0.29 to 1.94) · 2,408 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.78 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.68 (126.66 to 206.71) · 180 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 292 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.7 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.8 · 543 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 425 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 441 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 5,216 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.11 (0 to 0.29) · 9,948 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.45) · 10,968 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.04 (1.53 to 4.56) · 3,983 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.33 (0.2 to 2.46) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.78 (1.69 to 3.87) · 3,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.79 (6.29 to 13.29) · 2,100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.62 (4.04 to 9.2) · 2,018 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.63 (0.29 to 2.98) · 867 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.54 (0.07 to 1.01) · 8,613 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 294 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 598 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 924 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 8.5 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -18.3 · 638 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.4 · 443 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 600 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.9 to 6.1) · 992 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 298 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9 · 249 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.3 (8.7 to 14.6) · 1,326 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 934 cases | No different | Jan 2024 – Dec 2024 |
What patients said (700 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 77% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Sutter Roseville Medical Center
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 5 better, 1 the same, 1 worse of 7 measures. Readmissions: 2 better, 7 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.08 (0 to 0.56) · 12,400 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.069 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.128 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.357 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.33 (0.49 to 2.17) · 2,916 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.63 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 147.2 (107.33 to 187.07) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 250 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.7 · 484 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 839 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.3 · 1,027 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10 · 656 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 6,822 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.25 (0.08 to 0.42) · 14,300 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.06 to 0.41) · 14,490 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.43 (2.77 to 6.08) · 3,117 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.38 (0 to 2.95) · 938 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.76 to 3.36) · 2,944 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.03 (2.8 to 15.25) · 840 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.43 (3.11 to 9.75) · 899 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.73 (0.34 to 3.11) · 819 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 35 cases | None | Apr 2023 – Mar 2025 |
| SSI - Colon SurgeryInfections | 0.41 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 527 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 1,094 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -16.6 · 443 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 961 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8 · 1,064 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 1,293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.5 to 8.7) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (6.9 to 14.9) · 35 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 310 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.8 to 17.9) · 116 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,600 cases | No different | Jan 2024 – Dec 2024 |
What patients said (537 patients answered, 24% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 78% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$236,228
Medicare paid this office $236,228 for 999 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 653 | $112,731 | $101 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $46,062 | $166 |
| New patient visit (45+ min) | 141 | $17,874 | $127 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 687 | $12,533 | $13 |
| Long return visit (40+ min) | 51 | $8,792 | $149 |
See all 16 services
| Return visit (30+ min) | 653 | $112,731 | $101 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 266 | $46,062 | $166 |
| New patient visit (45+ min) | 141 | $17,874 | $127 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 687 | $12,533 | $13 |
| Long return visit (40+ min) | 51 | $8,792 | $149 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 32 | $6,520 | $204 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 115 | $6,381 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 530 | $6,154 | $11 |
| New patient visit (60+ min) | 17 | $2,641 | $155 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 46 | $2,230 | $19 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 36 | $2,143 | $23 |
| Heart muscle strain imaging | 30 | $1,060 | $32 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 28 | $651 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 68 | $520 | $7 |
| Ultrasound of heart, follow-up | 11 | $241 | $20 |
| Heart muscle strain imaging | 19 | $176 | $9 |
Who their Medicare patients are
999 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 18% · Women 57% · Also on Medicaid 14% · Health risk score 1.45. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 46% · Atrial fibrillation 38% · Chronic kidney disease 33% · Heart failure 30% · Diabetes 25% · COPD 23% · Depression 20% · Cancer 15% · Stroke 10% · Dementia 7%.
The office billed $988,592, Medicare allowed $313,531 and paid $236,228; for 3,826 services of 48 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 999 | 3,826 | 77 | 1.45 | $988,592 | $236,228 |
| 2023 | 707 | 1,543 | 77 | 1.44 | $450,562 | $101,978 |
| 2022 | 924 | 3,287 | 76 | 1.35 | $949,052 | $245,561 |
| 2021 | 1,018 | 2,784 | 76 | 1.42 | $653,398 | $223,218 |
| 2020 | 910 | 2,704 | 76 | 1.69 | $556,580 | $204,251 |
| 2019 | 959 | 2,195 | 75 | 1.81 | $390,903 | $154,730 |
| 2018 | 903 | 2,294 | 75 | 1.69 | $520,280 | $171,637 |
| 2017 | 1,206 | 2,422 | 76 | 1.42 | $434,695 | $113,699 |
| 2016 | 1,311 | 2,911 | 77 | 1.43 | $586,952 | $148,024 |
| 2015 | 1,295 | 2,819 | 77 | 1.52 | $790,453 | $181,630 |
| 2014 | 388 | 684 | 76 | 1.51 | $183,729 | $43,382 |
| 2013 | 97 | 173 | 66 | 2.37 | $42,141 | $12,102 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 532 | $55,946 | $83 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $17,727 | $157 |
| Long return visit (40+ min) | 40 | $5,352 | $124 |
| New patient visit (45+ min) | 43 | $5,023 | $117 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 303 | $2,909 | $9 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $2,876 | $205 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 47 | $2,651 | $56 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 26 | $668 | $20 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 19 | $646 | $25 |
| Heart muscle strain imaging | 12 | $373 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 50 | $313 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $296 | $21 |
2022: 19 services
| Return visit (30+ min) | 638 | $139,726 | $100 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 236 | $40,131 | $165 |
| New patient visit (45+ min) | 135 | $16,546 | $123 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 49 | $9,085 | $185 |
| Long return visit (40+ min) | 48 | $7,324 | $138 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 101 | $5,575 | $55 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 482 | $5,431 | $10 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 43 | $1,962 | $20 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,930 | $161 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 32 | $1,831 | $24 |
| Programming of dual lead pacemaker system | 24 | $1,058 | $31 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 122 | $934 | $7 |
| Ultrasound of heart blood flow, valves and chambers | 18 | $803 | $45 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 38 | $794 | $21 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 12 | $736 | $28 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 34 | $675 | $20 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 20 | $442 | $22 |
| Heart muscle strain imaging | 11 | $361 | $33 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring | 31 | $225 | $7 |
2021: 22 services
| Return visit (30+ min) | 603 | $99,611 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 165 | $27,271 | $162 |
| New patient visit (45+ min) | 147 | $19,206 | $131 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 188 | $11,274 | $58 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 28 | $9,853 | $352 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $6,950 | $165 |
| Long return visit (40+ min) | 45 | $6,381 | $139 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 388 | $5,012 | $12 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 28 | $4,977 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $3,919 | $83 |
| New patient visit (60+ min) | 19 | $3,485 | $183 |
| Short return visit (20+ min) | 67 | $3,296 | $47 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $2,852 | $204 |
| Injection, regadenoson, 0.1 mg | 15 | $2,849 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 33 | $1,724 | $52 |
| Programming of dual lead pacemaker system | 29 | $1,434 | $39 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,227 | $112 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 31 | $1,130 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 24 | $1,007 | $24 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 31 | $664 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 35 | $262 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 11 | $241 | $22 |
2020: 18 services
| Return visit (30+ min) | 321 | $47,207 | $85 |
| Short return visit (20+ min) | 334 | $28,349 | $57 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 159 | $27,585 | $167 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 288 | $18,253 | $63 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 45 | $15,519 | $323 |
| New patient visit (45+ min) | 86 | $11,843 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $10,737 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 89 | $10,186 | $113 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 45 | $8,048 | $89 |
| Injection, regadenoson, 0.1 mg | 34 | $6,413 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 180 | $2,814 | $14 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 45 | $2,407 | $53 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 15 | $2,403 | $160 |
| Programming of dual lead pacemaker system | 32 | $1,427 | $30 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 21 | $1,148 | $20 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $1,042 | $24 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 45 | $1,011 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 26 | $179 | $7 |
2019: 19 services
| Return visit (30+ min) | 216 | $32,003 | $88 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 155 | $25,489 | $162 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 352 | $21,235 | $60 |
| Short return visit (20+ min) | 229 | $19,158 | $59 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 55 | $10,493 | $187 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 92 | $10,143 | $108 |
| New patient visit (45+ min) | 74 | $9,682 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 81 | $9,529 | $84 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 134 | $2,064 | $14 |
| Programming of dual lead pacemaker system | 31 | $1,389 | $29 |
| Ultrasound of heart with probe in esophagus, with report | 14 | $1,265 | $90 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 17 | $1,045 | $19 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 42 | $921 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $830 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 107 | $758 | $7 |
| Ultrasound of heart, follow-up | 21 | $446 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $213 | $15 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $110 | $10 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $37 | $3 |
2018: 20 services
| Return visit (30+ min) | 214 | $31,344 | $81 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 183 | $30,748 | $164 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 307 | $18,614 | $60 |
| New patient visit (45+ min) | 142 | $17,297 | $122 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 69 | $13,493 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 69 | $11,247 | $163 |
| Short return visit (20+ min) | 135 | $10,667 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 69 | $8,236 | $85 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 16 | $6,598 | $412 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,331 | $111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 211 | $3,243 | $13 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 16 | $2,787 | $87 |
| Injection, regadenoson, 0.1 mg | 15 | $2,660 | None |
| Programming of dual lead pacemaker system | 29 | $1,361 | $30 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 17 | $902 | $53 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 30 | $661 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $641 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 74 | $505 | $7 |
| Electrocardiogram (ecg) 2-day continuous | 25 | $502 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 26 | $490 | $19 |
2017: 19 services
| Return visit (30+ min) | 217 | $21,844 | $80 |
| New patient visit (45+ min) | 154 | $19,201 | $125 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 307 | $15,059 | $49 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 73 | $13,180 | $181 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 92 | $5,004 | $54 |
| Short return visit (20+ min) | 84 | $4,632 | $53 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 272 | $3,681 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,303 | $107 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 165 | $2,862 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 333 | $2,385 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 164 | $1,929 | $12 |
| Programming of dual lead pacemaker system | 41 | $1,701 | $35 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 17 | $1,430 | $60 |
| New patient visit (30+ min) | 11 | $899 | $82 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 14 | $831 | $44 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 37 | $810 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 22 | $527 | $20 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 12 | $458 | $29 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 20 | $367 | $18 |
2016: 23 services
| Return visit (30+ min) | 261 | $32,588 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 130 | $25,034 | $187 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 306 | $15,926 | $51 |
| Short return visit (20+ min) | 176 | $12,701 | $59 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 37 | $8,206 | $222 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 128 | $7,454 | $58 |
| New patient visit (45+ min) | 58 | $7,079 | $122 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,430 | $111 |
| Programming of dual lead pacemaker system | 61 | $4,081 | $45 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 215 | $3,888 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 235 | $3,560 | $14 |
| Long return visit (40+ min) | 27 | $3,084 | $114 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 385 | $2,909 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 214 | $2,540 | $12 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 20 | $1,451 | $66 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 23 | $979 | $30 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 29 | $795 | $21 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 23 | $789 | $27 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 29 | $631 | $22 |
| Ultrasound of heart, follow-up | 13 | $317 | $21 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 11 | $229 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $76 | $7 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 11 | $66 | $6 |
2015: 19 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 214 | $40,527 | $187 |
| Return visit (30+ min) | 259 | $31,615 | $81 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 76 | $17,064 | $225 |
| New patient visit (45+ min) | 144 | $16,884 | $117 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 319 | $16,774 | $51 |
| Short return visit (20+ min) | 172 | $12,378 | $54 |
| Long return visit (40+ min) | 117 | $11,344 | $95 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 121 | $6,745 | $56 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 273 | $4,021 | $13 |
| Programming of dual lead pacemaker system | 71 | $3,522 | $38 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $3,226 | $111 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 33 | $2,378 | $68 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 290 | $2,152 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 169 | $1,922 | $11 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,077 | $57 |
| Programming of multiple lead implantable defibrillator system | 11 | $1,025 | $68 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 45 | $822 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 19 | $547 | $26 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 18 | $353 | $19 |
2014: 15 services
| New patient visit (45+ min) | 82 | $10,311 | $126 |
| Long return visit (40+ min) | 53 | $6,482 | $116 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 38 | $4,097 | $108 |
| Return visit (30+ min) | 37 | $3,689 | $88 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 17 | $3,150 | $185 |
| Short return visit (20+ min) | 35 | $2,264 | $60 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 43 | $2,242 | $52 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 109 | $1,596 | $14 |
| Ultrasound of heart during rest, exercise and/or drug-induced stress with report | 24 | $1,403 | $58 |
| New patient visit (45+ min) | 13 | $1,136 | $87 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $915 | $51 |
| Return visit (30+ min) | 14 | $858 | $57 |
| Programming of dual lead pacemaker system | 19 | $750 | $37 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 70 | $482 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 36 | $439 | $12 |
2013: 5 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 46 | $4,547 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,890 | $54 |
| Initial hospital observation care per day, typically 50 minutes | 14 | $1,419 | $101 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $909 | $29 |
| Hospital discharge day management, 30 minutes or less | 12 | $654 | $55 |
Medicaid work
$5,229 in 2024
Medicaid paid $5,229 for 108 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 35 | $3,538 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 44 | $1,151 |
| Return visit (30+ min) | 29 | $540 |
| 2024 | 108 | 3 | 18 | $5,229 |
| 2021 | 167 | 2 | 25 | $1,835 |
| 2020 | 110 | 1 | 18 | $2,238 |
| 2019 | 88 | 1 | 22 | $1,449 |
| 2018 | 254 | 4 | 23 | $2,069 |
See the largest Medicaid services in earlier years
2021
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 110 | $1,377 |
| Return visit (30+ min) | 57 | $458 |
2020
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 110 | $2,238 |
2019
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 88 | $1,449 |
2018
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 139 | $2,069 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 45 | $0 |
| New patient visit (45+ min) | 34 | $0 |
| Return visit (30+ min) | 36 | $0 |
Drugs they prescribed that Part D paid
$1,554,417
Pharmacies billed $1,554,417 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 6,258) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
5,045 generic and 1,213 brand-name prescriptions · $1,554,417 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 531 | $705,043 | $1,328 |
| Entresto | 161 | $216,508 | $1,345 |
| Xarelto | 133 | $197,799 | $1,487 |
| Repatha Sureclick | 103 | $105,506 | $1,024 |
| Farxiga | 82 | $82,050 | $1,001 |
See all 48 drugs
| Eliquis | 531 | $705,043 | $1,328 |
| Entresto | 161 | $216,508 | $1,345 |
| Xarelto | 133 | $197,799 | $1,487 |
| Repatha Sureclick | 103 | $105,506 | $1,024 |
| Farxiga | 82 | $82,050 | $1,001 |
| Jardiance | 52 | $64,301 | $1,237 |
| Multaq | 14 | $28,876 | $2,063 |
| Vascepa | 42 | $28,232 | $672 |
| Metoprolol | 799 | $12,455 | $16 |
| Rosuvastatin | 473 | $9,203 | $19 |
| Dabigatran Etexilate | 31 | $8,688 | $280 |
| Ezetimibe | 179 | $7,076 | $40 |
| Atorvastatin | 565 | $6,840 | $12 |
| Diltiazem 24hr Er (Cd) | 172 | $5,399 | $31 |
| Losartan | 343 | $3,971 | $12 |
| Amlodipine Besylate | 381 | $3,110 | $8 |
| Nebivolol | 44 | $2,718 | $62 |
| Flecainide Acetate | 52 | $2,315 | $45 |
| Lisinopril | 250 | $2,076 | $8 |
| Hydrochlorothiazide | 177 | $1,609 | $9 |
| Isosorbide Mononitrate Er | 68 | $1,428 | $21 |
| Digoxin | 61 | $1,426 | $23 |
| Amiodarone | 42 | $1,350 | $32 |
| Valsartan | 28 | $1,324 | $47 |
| Furosemide | 201 | $1,307 | $7 |
| Clopidogrel | 94 | $1,220 | $13 |
| Carvedilol | 136 | $1,220 | $9 |
| Hydralazine | 56 | $1,168 | $21 |
| Spironolactone | 143 | $1,143 | $8 |
| Bumetanide | 13 | $1,010 | $78 |
| Cartia Xt | 28 | $947 | $34 |
| Diltiazem | 39 | $908 | $23 |
| Metoprolol | 130 | $854 | $7 |
| Pravastatin | 60 | $700 | $12 |
| Potassium Chloride | 35 | $660 | $19 |
| Warfarin | 32 | $631 | $20 |
| Nitroglycerin | 47 | $551 | $12 |
| Dilt-Xr | 11 | $514 | $47 |
| Atenolol | 58 | $503 | $9 |
| Clonidine | 32 | $461 | $14 |
| Pantoprazole | 11 | $446 | $41 |
| Sotalol | 16 | $417 | $26 |
| Lovastatin | 19 | $319 | $17 |
| Ramipril | 13 | $308 | $24 |
| Olmesartan Medoxomil | 15 | $293 | $20 |
| Simvastatin | 18 | $264 | $15 |
| Verapamil Er | 11 | $226 | $21 |
| Propranolol | 11 | $104 | $9 |
Year by year
| 2024 | 6,258 | 879 | 0% (0) | 19% | $1,554,417 |
| 2023 | 5,929 | 800 | 0% (0) | 18% | $1,395,224 |
| 2022 | 5,434 | 865 | None | None | $1,012,553 |
| 2021 | 4,440 | 664 | None | 17% | $710,572 |
| 2020 | 4,001 | 480 | None | 18% | $573,091 |
| 2019 | 3,194 | 415 | None | 19% | $440,151 |
| 2018 | 2,234 | 394 | 0% (0) | 17% | $240,335 |
| 2017 | 2,066 | 408 | None | 22% | $210,477 |
| 2016 | 2,447 | 391 | None | 21% | $209,821 |
| 2015 | 1,907 | 313 | None | 17% | $93,231 |
| 2014 | 294 | 70 | 0% (0) | 16% | $10,181 |
| 2013 | 54 | 17 | None | 33% | $3,357 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 50 drugs
| Eliquis | 514 | $677,997 | $1,319 |
| Xarelto | 150 | $227,317 | $1,515 |
| Entresto | 95 | $135,510 | $1,426 |
| Repatha Sureclick | 65 | $63,268 | $973 |
| Farxiga | 41 | $43,507 | $1,061 |
| Multaq | 23 | $35,089 | $1,526 |
| Repatha Pushtronex | 18 | $21,625 | $1,201 |
| Jardiance | 11 | $20,107 | $1,828 |
| Metoprolol | 715 | $15,225 | $21 |
| Atorvastatin | 597 | $10,011 | $17 |
| Vascepa | 22 | $9,385 | $427 |
| Rosuvastatin | 336 | $7,859 | $23 |
| Ezetimibe | 169 | $7,498 | $44 |
| Diltiazem 24hr Er (Cd) | 158 | $7,398 | $47 |
| Losartan | 377 | $6,814 | $18 |
| Icosapent Ethyl | 13 | $6,178 | $475 |
| Dabigatran Etexilate | 16 | $5,144 | $321 |
| Flecainide Acetate | 60 | $3,571 | $60 |
| Amlodipine Besylate | 370 | $3,088 | $8 |
| Lisinopril | 250 | $2,760 | $11 |
| Potassium Chloride | 56 | $2,399 | $43 |
| Spironolactone | 161 | $2,336 | $15 |
| Furosemide | 251 | $2,231 | $9 |
| Carvedilol | 132 | $2,148 | $16 |
| Nebivolol | 22 | $2,058 | $94 |
| Digoxin | 65 | $1,921 | $30 |
| Clopidogrel | 83 | $1,698 | $20 |
| Metoprolol | 141 | $1,635 | $12 |
| Valsartan | 30 | $1,455 | $49 |
| Hydrochlorothiazide | 164 | $1,448 | $9 |
| Hydralazine | 68 | $1,436 | $21 |
| Amiodarone | 38 | $1,358 | $36 |
| Candesartan Cilexetil | 13 | $1,346 | $104 |
| Warfarin | 31 | $1,300 | $42 |
| Isosorbide Mononitrate Er | 63 | $1,183 | $19 |
| Cartia Xt | 23 | $1,154 | $50 |
| Diltiazem 24hr Er | 21 | $1,115 | $53 |
| Pravastatin | 60 | $1,043 | $17 |
| Atenolol | 45 | $817 | $18 |
| Pantoprazole | 12 | $796 | $66 |
| Diltiazem | 33 | $777 | $24 |
| Nitroglycerin | 36 | $719 | $20 |
| Sotalol | 12 | $715 | $60 |
| Clonidine | 38 | $618 | $16 |
| Fenofibrate | 11 | $599 | $54 |
| Bisoprolol | 12 | $583 | $49 |
| Olmesartan Medoxomil | 12 | $544 | $45 |
| Propranolol | 16 | $424 | $26 |
| Dilt-Xr | 16 | $423 | $26 |
| Simvastatin | 17 | $352 | $21 |
2022: 50 drugs
| Eliquis | 498 | $574,921 | $1,154 |
| Xarelto | 99 | $127,500 | $1,288 |
| Entresto | 60 | $79,713 | $1,329 |
| Repatha Pushtronex | 36 | $27,225 | $756 |
| Repatha Sureclick | 25 | $22,545 | $902 |
| Multaq | 12 | $14,973 | $1,248 |
| Metoprolol | 659 | $13,676 | $21 |
| Brilinta | 12 | $9,355 | $780 |
| Pradaxa | 15 | $8,341 | $556 |
| Atorvastatin | 525 | $7,350 | $14 |
| Ezetimibe | 136 | $7,080 | $52 |
| Rosuvastatin | 200 | $6,271 | $31 |
| Diltiazem 24hr Er (Cd) | 143 | $5,438 | $38 |
| Vascepa | 12 | $5,012 | $418 |
| Losartan | 362 | $4,742 | $13 |
| Flecainide Acetate | 36 | $3,707 | $103 |
| Nebivolol | 29 | $3,429 | $118 |
| Digoxin | 68 | $3,021 | $44 |
| Potassium Chloride | 78 | $2,920 | $37 |
| Carvedilol | 145 | $2,260 | $16 |
| Amlodipine Besylate | 321 | $2,258 | $7 |
| Spironolactone | 158 | $2,124 | $13 |
| Candesartan Cilexetil | 18 | $2,118 | $118 |
| Furosemide | 246 | $2,072 | $8 |
| Pravastatin | 113 | $2,068 | $18 |
| Lisinopril | 239 | $1,906 | $8 |
| Ranolazine Er | 14 | $1,846 | $132 |
| Hydralazine | 56 | $1,685 | $30 |
| Warfarin | 56 | $1,631 | $29 |
| Metoprolol | 154 | $1,488 | $10 |
| Midodrine | 14 | $1,356 | $97 |
| Diltiazem 24hr Er | 25 | $1,249 | $50 |
| Isosorbide Mononitrate Er | 52 | $1,230 | $24 |
| Hydrochlorothiazide | 174 | $1,188 | $7 |
| Amiodarone | 50 | $1,125 | $23 |
| Clopidogrel | 53 | $1,122 | $21 |
| Valsartan | 15 | $1,010 | $67 |
| Dilt-Xr | 28 | $1,000 | $36 |
| Pantoprazole | 20 | $816 | $41 |
| Atenolol | 49 | $744 | $15 |
| Diltiazem | 34 | $710 | $21 |
| Fenofibrate | 14 | $706 | $50 |
| Olmesartan Medoxomil | 16 | $593 | $37 |
| Nitroglycerin | 31 | $536 | $17 |
| Clonidine | 32 | $522 | $16 |
| Fenofibrate | 16 | $433 | $27 |
| Propranolol | 11 | $377 | $34 |
| Sotalol | 12 | $296 | $25 |
| Famotidine | 15 | $245 | $16 |
| Simvastatin | 20 | $151 | $8 |
2021: 53 drugs
| Eliquis | 393 | $407,156 | $1,036 |
| Xarelto | 55 | $67,701 | $1,231 |
| Repatha Pushtronex | 31 | $23,583 | $761 |
| Multaq | 21 | $21,281 | $1,013 |
| Entresto | 21 | $16,929 | $806 |
| Repatha Sureclick | 21 | $13,400 | $638 |
| Metoprolol | 536 | $12,402 | $23 |
| Praluent | 16 | $10,665 | $667 |
| Brilinta | 13 | $9,581 | $737 |
| Bystolic | 19 | $7,794 | $410 |
| Atorvastatin | 465 | $6,765 | $15 |
| Ezetimibe | 112 | $5,516 | $49 |
| Diltiazem 24hr Er (Cd) | 93 | $4,642 | $50 |
| Rosuvastatin | 102 | $4,289 | $42 |
| Vascepa | 12 | $4,236 | $353 |
| Diltiazem 24hr Er | 49 | $3,224 | $66 |
| Losartan | 229 | $3,202 | $14 |
| Flecainide Acetate | 23 | $2,793 | $121 |
| Pravastatin | 102 | $2,229 | $22 |
| Isosorbide Mononitrate Er | 69 | $2,115 | $31 |
| Lisinopril | 254 | $1,991 | $8 |
| Amiodarone | 35 | $1,805 | $52 |
| Amlodipine Besylate | 268 | $1,790 | $7 |
| Dilt-Xr | 37 | $1,784 | $48 |
| Clonidine | 13 | $1,742 | $134 |
| Hydralazine | 76 | $1,732 | $23 |
| Potassium Chloride | 51 | $1,703 | $33 |
| Carvedilol | 111 | $1,670 | $15 |
| Digoxin | 33 | $1,588 | $48 |
| Metoprolol | 147 | $1,522 | $10 |
| Bumetanide | 11 | $1,466 | $133 |
| Warfarin | 38 | $1,257 | $33 |
| Furosemide | 177 | $1,248 | $7 |
| Fenofibrate | 18 | $1,178 | $65 |
| Hydrochlorothiazide | 140 | $1,036 | $7 |
| Spironolactone | 88 | $991 | $11 |
| Irbesartan | 15 | $971 | $65 |
| Cilostazol | 14 | $939 | $67 |
| Cartia Xt | 11 | $700 | $64 |
| Fenofibrate | 21 | $663 | $32 |
| Clopidogrel | 49 | $656 | $13 |
| Sotalol | 17 | $627 | $37 |
| Clonidine | 27 | $591 | $22 |
| Propranolol | 18 | $584 | $32 |
| Diltiazem | 16 | $492 | $31 |
| Nitroglycerin | 30 | $440 | $15 |
| Famotidine | 12 | $416 | $35 |
| Pantoprazole | 16 | $415 | $26 |
| Atenolol | 23 | $350 | $15 |
| Tamsulosin | 16 | $295 | $18 |
| Olmesartan Medoxomil | 16 | $266 | $17 |
| Benazepril | 13 | $256 | $20 |
| Simvastatin | 26 | $224 | $9 |
2020: 43 drugs
| Eliquis | 362 | $327,743 | $905 |
| Xarelto | 80 | $70,053 | $876 |
| Repatha Pushtronex | 30 | $21,563 | $719 |
| Metoprolol | 514 | $15,397 | $30 |
| Fenofibrate | 31 | $9,318 | $301 |
| Atorvastatin | 395 | $7,264 | $18 |
| Flecainide Acetate | 36 | $5,700 | $158 |
| Ezetimibe | 98 | $5,571 | $57 |
| Bystolic | 14 | $3,917 | $280 |
| Losartan | 203 | $3,108 | $15 |
| Diltiazem 24hr Er (Cd) | 71 | $2,871 | $40 |
| Rosuvastatin | 68 | $2,330 | $34 |
| Diltiazem 24hr Er | 39 | $2,330 | $60 |
| Amlodipine Besylate | 276 | $2,317 | $8 |
| Isosorbide Mononitrate Er | 58 | $2,248 | $39 |
| Dilt-Xr | 43 | $2,176 | $51 |
| Digoxin | 45 | $2,069 | $46 |
| Pravastatin | 88 | $2,025 | $23 |
| Hydralazine | 58 | $1,915 | $33 |
| Lisinopril | 219 | $1,779 | $8 |
| Potassium Chloride | 41 | $1,758 | $43 |
| Furosemide | 176 | $1,644 | $9 |
| Carvedilol | 101 | $1,436 | $14 |
| Warfarin | 40 | $1,417 | $35 |
| Fenofibrate | 13 | $1,197 | $92 |
| Metoprolol | 112 | $1,151 | $10 |
| Hydrochlorothiazide | 109 | $1,036 | $10 |
| Cartia Xt | 16 | $1,025 | $64 |
| Spironolactone | 85 | $980 | $12 |
| Verapamil Er | 17 | $886 | $52 |
| Clopidogrel | 50 | $886 | $18 |
| Irbesartan | 14 | $795 | $57 |
| Sotalol | 20 | $582 | $29 |
| Amiodarone | 19 | $536 | $28 |
| Propranolol | 11 | $533 | $48 |
| Klor-Con 10 | 17 | $482 | $28 |
| Nitroglycerin | 35 | $458 | $13 |
| Tamsulosin | 19 | $404 | $21 |
| Benazepril | 24 | $388 | $16 |
| Atenolol | 19 | $317 | $17 |
| Famotidine | 17 | $317 | $19 |
| Simvastatin | 18 | $265 | $15 |
| Amoxicillin | 11 | $35 | $3 |
2019: 41 drugs
| Eliquis | 282 | $251,750 | $893 |
| Xarelto | 53 | $53,321 | $1,006 |
| Repatha Pushtronex | 13 | $15,798 | $1,215 |
| Metoprolol | 331 | $10,849 | $33 |
| Atorvastatin | 356 | $8,306 | $23 |
| Bystolic | 14 | $4,728 | $338 |
| Flecainide Acetate | 46 | $4,589 | $100 |
| Rosuvastatin | 54 | $3,776 | $70 |
| Ezetimibe | 55 | $3,586 | $65 |
| Dilt-Xr | 53 | $2,585 | $49 |
| Digoxin | 48 | $2,399 | $50 |
| Losartan | 140 | $2,010 | $14 |
| Amlodipine Besylate | 179 | $1,871 | $10 |
| Lisinopril | 180 | $1,776 | $10 |
| Potassium Chloride | 34 | $1,613 | $47 |
| Diltiazem 24hr Er | 34 | $1,574 | $46 |
| Pravastatin | 82 | $1,569 | $19 |
| Furosemide | 158 | $1,534 | $10 |
| Diltiazem 24hr Er (Cd) | 47 | $1,530 | $33 |
| Isosorbide Mononitrate Er | 42 | $1,250 | $30 |
| Carvedilol | 92 | $1,221 | $13 |
| Verapamil Er | 23 | $1,004 | $44 |
| Hydralazine | 29 | $965 | $33 |
| Metoprolol | 114 | $940 | $8 |
| Hydrochlorothiazide | 102 | $927 | $9 |
| Cartia Xt | 18 | $886 | $49 |
| Spironolactone | 75 | $862 | $11 |
| Sotalol | 11 | $740 | $67 |
| Toprol Xl | 26 | $737 | $28 |
| Nifedipine Er | 11 | $717 | $65 |
| Nitroglycerin | 35 | $716 | $20 |
| Clopidogrel | 41 | $688 | $17 |
| Fenofibrate | 16 | $593 | $37 |
| Warfarin | 32 | $589 | $18 |
| Irbesartan | 15 | $392 | $26 |
| Amiodarone | 22 | $354 | $16 |
| Tamsulosin | 12 | $322 | $27 |
| Famotidine | 17 | $314 | $18 |
| Atenolol | 15 | $210 | $14 |
| Simvastatin | 11 | $195 | $18 |
| Benazepril | 12 | $185 | $15 |
2018: 33 drugs
| Eliquis | 173 | $144,283 | $834 |
| Xarelto | 28 | $18,978 | $678 |
| Atorvastatin | 260 | $6,980 | $27 |
| Metoprolol | 193 | $6,957 | $36 |
| Digoxin | 39 | $2,863 | $73 |
| Diltiazem 24hr Er (Cd) | 47 | $1,810 | $39 |
| Ezetimibe | 23 | $1,700 | $74 |
| Amlodipine Besylate | 166 | $1,555 | $9 |
| Amiodarone | 30 | $1,259 | $42 |
| Flecainide Acetate | 20 | $1,208 | $60 |
| Lisinopril | 166 | $1,203 | $7 |
| Metoprolol | 122 | $1,031 | $8 |
| Dilt-Xr | 19 | $1,011 | $53 |
| Losartan | 87 | $994 | $11 |
| Potassium Chloride | 29 | $948 | $33 |
| Nifedipine Er | 12 | $884 | $74 |
| Furosemide | 119 | $870 | $7 |
| Spironolactone | 63 | $822 | $13 |
| Rosuvastatin | 15 | $819 | $55 |
| Pravastatin | 33 | $801 | $24 |
| Warfarin | 30 | $758 | $25 |
| Hydrochlorothiazide | 88 | $686 | $8 |
| Cartia Xt | 13 | $653 | $50 |
| Isosorbide Mononitrate Er | 18 | $634 | $35 |
| Valsartan | 19 | $618 | $33 |
| Tamsulosin | 24 | $602 | $25 |
| Sotalol | 15 | $584 | $39 |
| Carvedilol | 64 | $579 | $9 |
| Verapamil Er | 15 | $558 | $37 |
| Hydralazine | 15 | $292 | $19 |
| Nitroglycerin | 17 | $260 | $15 |
| Clopidogrel | 15 | $223 | $15 |
| Omeprazole | 16 | $95 | $6 |
2017: 27 drugs
| Eliquis | 185 | $111,214 | $601 |
| Xarelto | 30 | $25,735 | $858 |
| Pradaxa | 29 | $20,717 | $714 |
| Atorvastatin | 262 | $6,183 | $24 |
| Metoprolol | 115 | $4,341 | $38 |
| Digoxin | 64 | $3,605 | $56 |
| Potassium Chloride | 54 | $2,869 | $53 |
| Diltiazem 24hr Er | 47 | $1,777 | $38 |
| Metoprolol | 194 | $1,580 | $8 |
| Amlodipine Besylate | 163 | $1,281 | $8 |
| Flecainide Acetate | 11 | $1,139 | $104 |
| Furosemide | 125 | $1,106 | $9 |
| Valsartan | 26 | $1,099 | $42 |
| Cartia Xt | 27 | $1,069 | $40 |
| Amiodarone | 31 | $925 | $30 |
| Lisinopril | 112 | $853 | $8 |
| Losartan | 87 | $840 | $10 |
| Pravastatin | 24 | $746 | $31 |
| Hydrochlorothiazide | 72 | $727 | $10 |
| Carvedilol | 59 | $643 | $11 |
| Warfarin | 36 | $458 | $13 |
| Spironolactone | 44 | $437 | $10 |
| Sotalol | 15 | $257 | $17 |
| Clopidogrel | 12 | $214 | $18 |
| Simvastatin | 20 | $143 | $7 |
| Benazepril | 11 | $136 | $12 |
| Atenolol | 13 | $97 | $7 |
2016: 30 drugs
| Eliquis | 149 | $82,449 | $553 |
| Xarelto | 51 | $40,118 | $787 |
| Pradaxa | 36 | $22,446 | $623 |
| Atorvastatin | 299 | $7,596 | $25 |
| Potassium Chloride | 84 | $4,461 | $53 |
| Metoprolol | 105 | $3,516 | $33 |
| Benicar | 13 | $2,889 | $222 |
| Metoprolol | 294 | $2,516 | $9 |
| Diltiazem 24hr Er | 53 | $2,075 | $39 |
| Digoxin | 32 | $1,904 | $60 |
| Amlodipine Besylate | 150 | $1,694 | $11 |
| Valsartan | 18 | $1,656 | $92 |
| Furosemide | 170 | $1,395 | $8 |
| Diltiazem 24hr Cd | 28 | $1,349 | $48 |
| Pravastatin | 31 | $1,162 | $37 |
| Toprol Xl | 13 | $1,130 | $87 |
| Lisinopril | 154 | $1,123 | $7 |
| Carvedilol | 87 | $1,099 | $13 |
| Losartan | 97 | $1,042 | $11 |
| Hydrochlorothiazide | 107 | $938 | $9 |
| Amiodarone | 30 | $611 | $20 |
| Cartia Xt | 18 | $601 | $33 |
| Clopidogrel | 33 | $484 | $15 |
| Sotalol | 28 | $474 | $17 |
| Spironolactone | 45 | $472 | $10 |
| Warfarin | 43 | $432 | $10 |
| Simvastatin | 33 | $318 | $10 |
| Isosorbide Mononitrate Er | 15 | $200 | $13 |
| Atenolol | 13 | $156 | $12 |
| Benazepril | 13 | $146 | $11 |
2015: 27 drugs
| Eliquis | 54 | $26,153 | $484 |
| Xarelto | 33 | $20,734 | $628 |
| Pradaxa | 15 | $8,974 | $598 |
| Atorvastatin | 254 | $4,387 | $17 |
| Valsartan | 11 | $2,393 | $218 |
| Amiodarone | 23 | $2,350 | $102 |
| Potassium Chloride | 59 | $1,697 | $29 |
| Metoprolol | 284 | $1,675 | $6 |
| Metoprolol | 44 | $1,577 | $36 |
| Cartia Xt | 33 | $1,125 | $34 |
| Digoxin | 17 | $1,059 | $62 |
| Diltiazem 24hr Er | 32 | $935 | $29 |
| Amlodipine Besylate | 168 | $920 | $5 |
| Furosemide | 121 | $915 | $8 |
| Losartan | 88 | $814 | $9 |
| Diltiazem 24hr Cd | 34 | $797 | $23 |
| Carvedilol | 100 | $728 | $7 |
| Lisinopril | 126 | $697 | $6 |
| Pravastatin | 30 | $622 | $21 |
| Hydrochlorothiazide | 80 | $538 | $7 |
| Clopidogrel | 33 | $511 | $15 |
| Sotalol | 25 | $430 | $17 |
| Warfarin | 21 | $303 | $14 |
| Nitrostat | 12 | $251 | $21 |
| Hydralazine | 19 | $230 | $12 |
| Spironolactone | 33 | $188 | $6 |
| Isosorbide Mononitrate Er | 18 | $158 | $9 |
2014: 8 drugs
| Atorvastatin | 28 | $954 | $34 |
| Metoprolol | 51 | $305 | $6 |
| Lisinopril | 33 | $275 | $8 |
| Potassium Chloride | 13 | $231 | $18 |
| Hydrochlorothiazide | 23 | $165 | $7 |
| Amlodipine Besylate | 18 | $155 | $9 |
| Carvedilol | 16 | $145 | $9 |
| Furosemide | 21 | $117 | $6 |
Money from drug and device companies
$236 in 2025
| 2025 | 3 | 3 | None | $236 |
| 2024 | 1 | 1 | None | $179 |
| 2023 | 1 | 1 | None | $125 |
| 2022 | 2 | 3 | None | $257 |
| 2021 | 8 | 12 | None | $311 |
| 2020 | 9 | 19 | None | $328 |
| 2019 | 10 | 88 | None | $1,001 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Edwards Lifesciences | Sapien 3 Ultra Resilia | $173 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $47 | 1 payment
|
| Boston Scientific | Rotablator Rotational Atherectomy System Console Kit | $16 | 1 payment
|
See all 3 published payments
| Boston Scientific | Meals · 2025-09-08 | Rotablator Rotational Atherectomy System Console Kit | $16 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-02-07 | Lifevest | $47 |
| Edwards Lifesciences | Meals · 2025-01-29 | Sapien 3 Ultra Resilia | $173 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $179
| Atricure | Synergy Ablation System | $179 | 1 payment
|
2023: $125
| E.R. Squibb & Sons L.L.C. | Camzyos | $125 | 1 payment
|
2022: $257
| Abbott Laboratories | Mitraclip | $156 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $101 | 1 payment
|
2021: $311
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $120 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $34 | 2 payments
|
| Amarin Pharma | Vascepa | $33 | 2 payments
|
| Janssen Pharmaceuticals | Xarelto | $32 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $32 | 2 payments
|
| HeartFlow | Ffrct | $25 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $25 | 1 payment
|
| Esperion Therapeutics | Nexletol | $11 | 1 payment
|
2020: $328
| Novartis Pharmaceuticals | Entresto | $68 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $59 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $48 | 3 payments
|
| Amgen | Corlanor | $37 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $32 | 2 payments
|
| Amarin Pharma | Vascepa | $29 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $15 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $15 | 1 payment
|
2019: $1,001
| Amgen | Repatha | $216 | 18 payments
|
| Janssen Pharmaceuticals | Xarelto | $137 | 13 payments
|
| Novartis Pharmaceuticals | Entresto | $125 | 14 payments
|
| Pfizer | Eliquis | $124 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $114 | 7 payments
|
| Boehringer Ingelheim Pharmaceuticals | Pradaxa | $105 | 5 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $68 | 5 payments
|
| Sanofi-Aventis U.S. | Multaq | $63 | 4 payments
|
| Regeneron Healthcare Solutions | Praluent | $28 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $20 | 1 payment
|
Professional record
- NPI
- 1003083031
- Licence
- CA A127503California A127503: Current · expires 2027-02-28
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- Po Box 255228, Sacramento, CA, 95865
- NPI first listed
- 2008-05-08
- NPI last updated
- 2021-08-27
- NPI record certified
- 2021-08-27
This is when the NPI record was last certified, not a medical board exam.